Pharmacokinetics of metrifonate and its metabolite dichlorvos in healthy volunteers and in patients with renal impairment

Clinical Drug Investigation

Volumn 18, Issue 1, 1999, Pages 35-46

  Heinig, Roland ^a   Dietrich, Hartmut ^a   Halabi, Atef ^b  

^a BAYER AG   (Germany)

^b Clin Pharma Research AG (CPR)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; DICHLORVOS; METRIFONATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSIS; DIARRHEA; DRUG ELIMINATION; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; ERYTHROCYTE; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; URINARY EXCRETION;

EID: 0032769080     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918010-00005     Document Type: Article

References (17)

1. 1. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
2. 2. Cummings JL, Cyrus PA, Bieber F, et al., and the Metrifonate Study Group. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50: 1214-21
3. 3. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996; 21: 331-7
4. 4. Nordgren I, Holmstedt B, Bengtsson E, et al. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with Bilarcil®. Am J Trop Med Hyg 1980; 29: 426-30
5. 5. Andreucci VE. Russo D, Cianciaruso B, et al. Some sodium, potassium and water changes in the elderly and their treatment. Nephrol Dial Transplant 1996; 11 Suppl. 9: 9-17
6. 6. Villén T, Abdi YA, Ericsson O, et al. Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas-chromatography-mass spectrometry. J Chromatogr 1990; 529: 309-17
7. 7. Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95
8. 8. Knedel M, Böttger R. Eine kinetische Methode zur Bestimmung der Aktivität der Pseudocholinesterase. Klin Wochensehr 1967; 45: 325-7
9. 9. Edwards G, Breckenridge AM. Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet 1988; 15: 67-93
10. 10. Abdi YA, Villén T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 1991; 68: 137-9
11. 11. Pettigrew LC, Bicher K, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998; 38: 236-45
12. 12. Abdi YA, Villén T, Ericsson Ö, et al. Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects. Bull World Health Organ 1990; 68: 731-6
13. 13. Nordgren I, Bengtsson E, Holmstedt B, et al. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil®. Acta Pharmacol Toxicol (Copenh) 1981; 29 Suppl. 5: 79-86
14. 14. Heinig R, Boettcher M, Herman-Gnjidic Z, et al. The effects of a magnesium/aluminium hydroxide-containing antacid, cimetidine or ranitidine on the pharmacokinetics of metrifonate and its metabolite DDVP. Clin Drug Invest 1999; 17 (1): 67-77
15. 15. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci 1998; 62 (16): 1433-41
16. 16. McKeith IG. The clinical trial protocol of the metrifonate in Alzheimer's trial (MALT). Dement Geriatr Cogn Disord 1998; 9 Suppl. 2: 2-7
17. 17. Heinig R, Versavel M, Breuel HP, et al. Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers [abstract no. 39-26 and poster]. 6th World Congress of Biological Psychiatry; 1997 June 22-27: Nice, France, Abstract Biol Psychiatry 1997; 42 Suppl. 1: 94S